SAREPTA THERAPEUTICS, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
SAREPTA THERAPEUTICS, INC. (SRPT) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $1.43 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Equity
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2024-02-28
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2021-06-30 was $1.43M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2019-09-30 was $3.45M, a 4.39% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2019-03-31 was $889.00K.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2018-09-30 was $3.30M.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2021 was $1.43M, a 77.39% decline from fiscal 2020.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2020 was $6.33M, a 30.67% decline from fiscal 2019.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2019 was $9.13M, a 0.82% increase from fiscal 2018.
- SAREPTA THERAPEUTICS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2018 was $9.06M, a 306.87% increase from fiscal 2017.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month as first filed |
|---|---|---|---|---|
| 2021-12-31 | $1.43M 10-K · filed 2024-02-28 | |||
| 2021-06-30 | $1.43M 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | $6.33M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $9.13M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $3.45M 10-Q · filed 2020-11-05 | |||
| 2019-03-31 | $889.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $9.06M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $3.30M 10-Q · filed 2019-11-07 | $9.05M derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $5.75M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $2.23M 10-K · filed 2020-02-26 | |||
| 2016-12-31 | $2.17M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $182.00K 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $34.00K 10-K · filed 2017-02-28 | |||
| 2013-12-31 | $226.00K 10-K · filed 2016-02-25 | -$226.00K 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |